PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd.specializes in studies using PXB mice, a high-quality human hepatocyte chimeric mouse model. The following summarizes the features of PhoenixBio Co., Ltd.’s nonclinical studies, an example of a disease model, and representative case studies. Use this information when evaluating contract research providers.

Features ofPhoenixBio Co., Ltd.’s Contract Non-Clinical Testing Services

Use of human hepatocyte chimeric mice (PXB mice)

PhoenixBio Co., Ltd. specializes in nonclinical studies using PXB mice. In this model, ≥70% of the liver is replaced with human hepatocytes, which more closely reflects drug metabolism in humans. This enables pharmaceutical sponsors to obtain reliable data to evaluate the efficacy and safety of new compounds under conditions that closely approximate human physiology.

Extensive animal disease models

PhoenixBio Co., Ltd. maintains a diverse portfolio of animal disease models and conducts nonclinical studies across a broad range of indications. In new drug development targeting specific diseases, PhoenixBio selects appropriate models and conducts rapid, efficient efficacy evaluations, enabling timely generation of the required data.

High-quality safety and efficacy/pharmacology studies

Safety studies and efficacy/pharmacology studies are conducted in accordance with applicable guidelines, providing reliable data for critical stages of drug development.

Examples of Disease Models Offered by PhoenixBio Co., Ltd.

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

MASH Disease Model – "MASH-c/PXB® Mouse"

A NASH-like disease model generated by feeding PXB mice (human hepatocyte chimeric mice) a CDAHFD diet (choline-deficient, amino acid-restricted, very high-fat diet) for 12 weeks. Hepatocyte ballooning and Mallory–Denk–like bodies can be observed, along with inflammatory responses and elevated human ALT-1.

NASH disease model: “NASH-g/PXB mouse”

A NASH-like disease model generated by feeding human hepatocyte chimeric mice a GAN diet for 30 weeks. Hepatocyte ballooning and Mallory–Denk–like bodies can be observed, along with inflammatory responses and elevated human ALT-1.

PhoenixBio Co., Ltd. Non-Clinical Case Studies

Human PK prediction (quantitative prediction)

PXB mice, monkeys, and rats were used to compare and evaluate predicted human clearance for 30 compounds. By comparing initial pharmacokinetic parameters, it is possible to assess absorption from the gastrointestinal tract, distribution to tissues, hepatic metabolism, and urinary elimination. This assessment supports the design of drugs with favorable efficacy and safety profiles and the planning of appropriate clinical studies.

Human metabolite prediction (qualitative prediction)

Lamotrigine was used to predict human metabolites by comparing data from PXB mice with control mice. By observing the in vivo time course, blood-level monitoring and the effects of multi-drug co-administration can be evaluated.

PhoenixBio Co., Ltd. Company Information

PhoenixBio Co., Ltd. is developing a new business that provides human hepatocyte functionality in an easy-to-use format for a variety of applications. The company consistently produces more than 4,000 PXB mice per year.